Home > Products > Antibodies > Bispecific Antibodies

Research Grade Vudalimab (HS870226)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HS870226
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHumanized
Isotypehalf-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
Expression systemMammalian Cells
ClonalityMonoclonal
TargetProgrammed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Concentration1mg/ml
Endotoxin levelPlease contact the lab for this information.
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G, purified from cell culture supernatant.
AccessionQ15116 & P16410
FormLiquid
Storage buffer0.01M PBS,pH7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -663°C.
Alternate NamesBispecific,XmAb-20717,XMAB20717,CAS:2329669-72-7
BackgroundVudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
NoteFor research use only. Not for use in clinical or therapeutic applications.
Images
  • Bioactivity

    Detects CD279/PDCD1/PD1 in indirect ELISAs.

References

Recommendation